policy
No description yet: the sentence for this tag has not been written. 5 records carry it: 3 terms, 2 people.
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Christopher M. Booth Professor of Oncology and Public Health Sciences, Queen's University; Medical Oncologist, Kingston Health Sciences Centre · Queen's University / Kingston Health Sciences Centre Oncologist who co-led CHALLENGE and founded Common Sense Oncology to refocus trials on outcomes that matter to patients. | Colorectal cancer | none | evidence, exercise | ||
Jonathan Benger Chief Executive of NICE (since December 2025) · National Institute for Health and Care Excellence Emergency physician who became Chief Executive of NICE, the body that appraises new cancer medicines and issues clinical guidance for the NHS, in December 2025. | none | none | leadership, clinician-scientist, hta | ||
Oncology drug pricing and price transparency New cancer drugs commonly launch above $150,000-$250,000 per year in the US, with prices set without reference to benefit and hidden behind rebates; other countries negotiate or assess cost-effectiveness. Pricing policy determines who gets treated. | none | none | none | ||
Oncology workforce There are not enough oncologists, radiation therapists, pathologists, oncology nurses and pharmacists for the growing number of patients, in rich countries and especially in poor ones; burnout, geography and training pipelines shape who receives care. | none | none | none | ||
WHO Essential Medicines List for cancer The World Health Organization's list of medicines every health system should provide, which now includes about 60 cancer drugs from cyclophosphamide and cisplatin to trastuzumab, imatinib and PD-1 inhibitors, guiding procurement and pricing in lower-income countries. | none | none | global |